These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 9759581)

  • 21. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
    Najjar YG; Puligandla M; Lee SJ; Kirkwood JM
    Cancer; 2019 Sep; 125(17):3013-3024. PubMed ID: 31067358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
    Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
    J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
    Kirkwood JM; Resnick GD; Cole BF
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.
    Ascierto PA; Daponte A; Parasole R; Perrone F; Caracò C; Melucci M; Palmieri G; Napolitano M; Mozzillo N; Castello G
    Cancer; 2000 Oct; 89(7):1490-4. PubMed ID: 11013362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of failure in patients with malignant melanoma treated with high-dose interferon-alpha2b in the adjuvant setting.
    Schachter J; Brenner B; Fenig E; Gutman R; Sulkes A; Gutman H
    Melanoma Res; 2003 Feb; 13(1):93-6. PubMed ID: 12569291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
    Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
    Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
    Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
    J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
    Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E
    J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interferons and malignant melanoma].
    Dreno B
    Rev Med Interne; 2002 Nov; 23 Suppl 4():489s-493s. PubMed ID: 12481404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.
    Kilbridge KL; Cole BF; Kirkwood JM; Haluska FG; Atkins MA; Ruckdeschel JC; Sock DE; Nease RF; Weeks JC
    J Clin Oncol; 2002 Mar; 20(5):1311-8. PubMed ID: 11870174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.
    González-Larriba JL; Serrano S; Alvarez-Mon M; Camacho F; Casado MA; Díaz-Pérez JL; Díaz-Rubio E; Fosbrook L; Guillem V; López-López JJ; Moreno-Nogueira JA; Toribio J
    Eur J Cancer; 2000 Dec; 36(18):2344-52. PubMed ID: 11094308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
    Verma S; Quirt I; McCready D; Bak K; Charette M; Iscoe N
    Cancer; 2006 Apr; 106(7):1431-42. PubMed ID: 16511841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in the care of the patient with malignant melanoma.
    Reintgen D; Balch CM; Kirkwood J; Ross M
    Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
    Gale DM; Kiley KE
    Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.
    Lens M
    Dermatol Ther; 2006; 19(1):9-18. PubMed ID: 16405565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
    Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
    J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.